Chromophobe Renal Cell Carcinoma Clinical Trials

14 clinical trials for Chromophobe Renal Cell Carcinoma across international registries, including 3 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors — RECRUITING · PHASE2
• An Investigation of Kidney and Urothelial Tumor Metabolism in Patients Undergoing Surgical Resection and/or Biopsy — RECRUITING · NA
• A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit — RECRUITING · PHASE1
• Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study — ACTIVE_NOT_RECRUITING · PHASE2
• Cabozantinib In Combo With NIVO + IPI In Advanced NCCRCC — ACTIVE_NOT_RECRUITING · PHASE2
• Cabozantinib or Sunitinib Malate in Treating Participants With Metastatic Variant Histology Renal Cell Carcinoma — ACTIVE_NOT_RECRUITING · PHASE2
• Identification of Novel High Quality Methylated DNA Markers in Renal Tumors: Whole Methylome Discovery, Tissue Validation, and Feasibility Testing In Blood and Urine, The INQUIRE Study — COMPLETED
• Memory-like Natural Killer (NK) Cell Therapy in Patients With Renal Cell Carcinoma or Urothelial Carcinoma — ACTIVE_NOT_RECRUITING · PHASE1
• Tumor-Derived Extracellular Vesicles for Noninvasive Molecular Classification of Kidney Cancer — NOT_YET_RECRUITING
• A Study of Nivolumab In Combination With Cabozantinib in Patients With Non-Clear Cell Renal Cell Carcinoma — ACTIVE_NOT_RECRUITING · PHASE2
• ANZUP - Non-clear Cell Post Immunotherapy CABozantinib (UNICAB) — COMPLETED · PHASE2
• Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer — COMPLETED · PHASE2
• Phase II Sequential Treatment Trial of Single Agent Nivolumab, Then Combination Ipilimumab + Nivolumab in Metastatic or Unresectable Non-Clear Cell Renal Cell Carcinoma (ANZUP1602) — OTHER · PHASE2
• Sorafenib Tosylate and Bevacizumab in Treating Patients With Advanced Kidney Cancer — COMPLETED · PHASE1

Refine this search